DMD Focus Upsher-Smith is actively expanding Duchenne muscular dystrophy therapies, with recent launches of Dexamethasone Otic Suspension and corticosteroid treatments, plus patient support websites for Kymbee. This indicates a strong opportunity for sales partnerships with DMD clinics, specialty pharmacies, and patient advocacy groups, including distribution agreements and patient assistance programs.

Rare Disease Growth The company concentrates on generics and specialty medicines for rare and complex conditions, suggesting a demand for targeted distribution, hospital channel access, and specialty pharmacy partnerships to reach niche patient populations; explore value-based contracts and access programs.

Europe Footprint The closure of the Plymouth UK facility and workforce reductions highlight a shifting European footprint, presenting an opportunity to engage regional distributors, contract manufacturers, or service providers to ensure continued European access and supply for Upsher-Smith products.

Digital Patient Engagement With patient-focused DMD support initiatives and a tech stack that includes digital tools, there is scope to partner on digital adherence programs, patient education portals, and data-driven outcome insights to support payer negotiations and improve therapy uptake.

Strategic Partnerships As the Bora Group's commercial arm with strong healthcare system partnerships, Upsher-Smith may be open to co-promotion, licensing, or distribution collaborations for new products and pipeline assets, leveraging existing commercial execution to accelerate market access.